Comparison of intra-arterial chemotherapy with gemcitabine or floxuridine followed by TACE with oxaliplatine

Hepatitis Monthly

Volumn 9, Issue 4, 2009, Pages 253-260

  Hao, Ming Zhi ^a   Chen, Qiang ^a   Lin, Hai Lan ^a   Wu, Hui ^a   Chen, Qi Zhong ^a   Li, Jian Cheng ^a   Zheng, Jian Xiong ^a   Ye, Yun Bin ^a  

^a FUJIAN PROVINCIAL TUMOR HOSPITAL   (China)

Author keywords

Floxuridine; Gemcitabine; Hepatocellular carcinoma; Oxaliplatin; Oxaliplatin lipiodol emulsion; Transcatheter arterial chemoembolization

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FLOXURIDINE; GEMCITABINE; IODINATED POPPYSEED OIL; OXALIPLATIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INOPERABLE CANCER; LEUKOPENIA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 74049096787     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153-6.
2. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38(2):200-7.
3. Konno T, Maeda H, Iwai K, et al. Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol. 1983;19(8):1053-65.
4. Ohishi H, Uchida H, Yoshimura H, et al. Hepatocellular carcinoma detected by iodized oil. Use of anticancer agents. Radiology. 1985;154(1):25-9.
5. Yumoto Y, Jinno K, Tokuyama K, et al. Hepatocellular carcinoma detected by iodized oil. Radiology. 1985;154(1):19-24.
6. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002; 359(9319):1734-9.
7. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164-71.
8. Taieb J, Mansourbakht T, Ducreux M, et al., editors. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma (AHCC): results of a phase II study. Journal of Clinical Oncology ASCO Annual Meeting Proceedings (Post-Meeting Edition); 2004.
9. Bearz A, Sorio R, Tommasi G, et al. Oxaliplatin and 5-fluorouracil in hepatocarcinoma. Proc Am Soc Clin Onco. 2001;20:148b.
10. Yang TS, Lin YC, Chen JS, Wang HM, Wang CH. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer. 2000;89(4):750-6.
11. Horiuchi H, Ishikawa H, Hiraki M, et al. [Intraarterial chemotherapy with gemcitabine (GEM) for unresectable pancreatic cancer]. Gan To Kagaku Ryoho. 2002;29(12):2065-9.
12. Vogl TJ, Heller M, Zangos S, et al. [Transarterial chemoperfusion of inoperable pancreas carcinoma and local recurrence]. Rofo. 2003;175(5):695-704.
13. Shamseddine AI, Khalifeh MJ, Mourad FH, et al. Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients. Clin Pharmacokinet. 2005;44(9):957-67.
14. Yang BH. [The Diagnosing and Staging National Standards for hepatocellular carcinoma]. Zhonghua Ganzangbing Zazhi. 2001;9(6):324-9.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-16.
16. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37(2):429-42.
17. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30(5):969-77.
18. Wall JG, Benedetti JK, O'Rourke MA, Natale RB, Macdonald JS. Phase II trial to topotecan in hepatocellular carcinoma: a Southwest Oncology Group study. Invest New Drugs. 1997;15(3):257-60.
19. O'Reilly EM, Stuart KE, Sanz-Altamira PM, et al. A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer. 2001;91(1):101-5.
20. Rougier P, Ducreux M, Kerr D, et al. A phase II study of raltitrexed ('Tomudex') in patients with hepatocellular carcinoma. Ann Oncol. 1997;8(5):500-2.
21. Chao Y, Chan WK, Birkhofer MJ, et al. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer. 1998;78(1):34-9.
22. Ueno K, Miyazono N, Inoue H, Nishida H, Kanetsuki I, Nakajo M. Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors. Cancer. 2000;88(7): 1574-81.
23. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56(4):918-28.
24. Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer. 1989;64(8):1700-7.
25. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-34.